Evidence check: Pharmakogenetik Medicheck in the context of Fruchtbarkeit

The pharmacogenetics Medicheck in the context of fertility claims to identify genetic variants that affect the metabolism of hormone or fertility drugs. However, the scientific evidence is limited. While some SNPs in CYP2C19, CYP2D6, or FSH receptor genes may modulate the efficacy of clomiphene, letrozole, or gonadotropins, effect sizes are generally small and clinical relevance remains unclear. Most studies are mechanistic or observational; randomized controlled trials are lacking. Commercial tests often overlook polygenicity and environmental factors. A positive result should not lead to self-adjustment of medication. Pharmacogenetics in reproductive medicine is an emerging field but not yet standard practice. Medical supervision is essential. The evidence is rated as 'mixed': there are mechanistic and GWAS data, but insufficient validation for routine use.